CompletedPhase 3

Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo

1,141 participantsStarted 1996-12

Plain-language summary

The objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects who expected to suffer at least one acute attack of migraine, with or without aura, each 6 weeks (The diagnosis of migraine was to comply with the criteria proposed by the International Headache Society (IHS)) * Subjects capable of taking medication as outpatients, and recording the effects of such medication. Exclusion Criteria: * Pregnant or breast-feeding women * Migraine subjects who also suffered from concomitant frequent (non-migrainous) headache, defined as more than six attacks per month on average.

What they're measuring

Headache response at 1 hour after the first dose for the first attack.

Timeframe: 1 hour

Trial details

NCT IDNCT01986270

SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion1998-01

View on ClinicalTrials.gov More Migraine With or Without Aura trials